Navigation Menu

Clinical Trial External Search


Children (age < 18 years)
Adults (age >= 18 years)

Researcher Profile

Researcher Display

Ian Zagon, MS, PhD

Ian Zagon, MS, PhD

Distinguished Professor, Department of Neuroscience and Experimental Therapeutics
Penn State Neuroscience Institute
Scientific Program:Next-Generation Therapies
ISZ1@psu.edu

Recent Publications

2025

Kimchi, ET, Kaifi, JT, Jiang, Y, Li, G, Avella, DM, Gusani, NJ, Schreibman, I, Waybill, P, McLaughlin, P, Zagon, IS, Smith, JP & Staveley-O’Carroll, KF 2025, 'A Phase I Study of the Naturally Occurring Bioactive, Opioid Growth Factor, in Patients with Unresectable Hepatocellular Cancer', Cancer Investigation, vol. 43, no. 3, pp. 224-235. https://doi.org/10.1080/07357907.2025.2484774
Odom, LB, Thomas, GA, Zachariah, JJ, Zagon, IS & McLaughlin, PJ 2025, 'Exploring the relationships of physical, mental, and emotional symptoms and serum biomarkers of angiogenesis in multiple sclerosis', Multiple Sclerosis Journal - Experimental, Translational and Clinical, vol. 11, no. 2. https://doi.org/10.1177/20552173251329904
Diaz, D, Sassani, JW, Zagon, IS & McLaughlin, PJ 2025, 'Reversal of Diabetic Dry Eye by Topical Opioid Receptor Blockade Follows Dual Pathways', Investigative Ophthalmology and Visual Science, vol. 66, no. 3, 24. https://doi.org/10.1167/iovs.66.3.24

2024

Diaz, D, Sassani, JP, Zagon, IS & McLaughlin, PJ 2024, 'Topical naltrexone increases aquaporin 5 production in the lacrimal gland and restores tear production in diabetic rats', Experimental Biology and Medicine, vol. 249, 10175. https://doi.org/10.3389/ebm.2024.10175

2023

McLaughlin, PJ, Sassani, JW & Zagon, IS 2023, 'Safety study of topical naltrexone therapy for diabetic skin wounds is confirmed in Göttingen mini-pigs', Drug Development Research, vol. 84, no. 6, pp. 1279-1284. https://doi.org/10.1002/ddr.22086

2022

McLaughlin, PJ, Odom, LB, Arnett, PA, Orehek, S, Thomas, GA & Zagon, IS 2022, 'Low-dose naltrexone reduced anxiety in persons with multiple sclerosis during the COVID-19 pandemic', International Immunopharmacology, vol. 113, 109438. https://doi.org/10.1016/j.intimp.2022.109438